ENDRA Life Sciences (NDRA) Cash & Equivalents (2016 - 2021)
Historic Cash & Equivalents for ENDRA Life Sciences (NDRA) over the last 6 years, with Q3 2021 value amounting to $11.8 million.
- ENDRA Life Sciences' Cash & Equivalents rose 21089.58% to $11.8 million in Q3 2021 from the same period last year, while for Sep 2021 it was $11.8 million, marking a year-over-year increase of 21089.58%. This contributed to the annual value of $7.2 million for FY2020, which is 1705.66% up from last year.
- Per ENDRA Life Sciences' latest filing, its Cash & Equivalents stood at $11.8 million for Q3 2021, which was up 21089.58% from $14.0 million recorded in Q2 2021.
- In the past 5 years, ENDRA Life Sciences' Cash & Equivalents ranged from a high of $16.8 million in Q1 2021 and a low of $133679.0 during Q1 2017
- Over the past 5 years, ENDRA Life Sciences' median Cash & Equivalents value was $3.9 million (recorded in 2019), while the average stood at $5.5 million.
- Per our database at Business Quant, ENDRA Life Sciences' Cash & Equivalents surged by 913641.11% in 2017 and then tumbled by 9086.88% in 2018.
- Quarter analysis of 5 years shows ENDRA Life Sciences' Cash & Equivalents stood at $5.6 million in 2017, then grew by 15.52% to $6.5 million in 2018, then decreased by 4.59% to $6.2 million in 2019, then grew by 17.06% to $7.2 million in 2020, then skyrocketed by 63.18% to $11.8 million in 2021.
- Its Cash & Equivalents stands at $11.8 million for Q3 2021, versus $14.0 million for Q2 2021 and $16.8 million for Q1 2021.